Ocular Tx (OCUL) Q3 2026 Earnings Call Transcript
Ocular Tx (OCUL) discussed Q3 2026 earnings, highlighting AXPAXLI's Phase III data in wet AMD. The company emphasized its drug's potency, delivery system, and clinical trial design. OCUL plans to submit an NDA in Q4 2026, aiming for a 505(b)(2) regulatory pathway. SOL-R trial updates showed promising results, with 70% of subjects dry at week 36.
How this was made

The 30-second read
Why it matters
The call frames a near-term catalyst (Q4 NDA submission) and outlines the evidence package (week 52 efficacy, safety, repeat-dosing data) plus an FDA pathway intended to shorten review time.
Market read
Traders can update probabilities around regulatory timing and evidence sufficiency for AXPAXLI based on management’s stated NDA plan and safety database scope.
What to watch
Key near-term risk is whether FDA accepts the 505(b)(2) strategy and whether interim SOL-R safety analysis and repeat-dosing data meet expectations; the excerpt also ends mid-sentence, suggesting additional details may alter the risk assessment.
Background
Ocular Therapeutix is discussing AXPAXLI (axitinib sustained-release via bioresorbable hydrogel) development in wet AMD, including SOL-1 and SOL-R Phase III trial design and regulatory planning.
Ticker impact
Ocular’s Q3 2026 earnings call details AXPAXLI Phase III wet AMD progress, including planned Q4 NDA submission and SOL-R/SOL-1 durability and safety plans.
Likely upward bias as traders price in a clearer regulatory path and additional confirmatory data for AXPAXLI.
The article is a call transcript with specific, decision-relevant milestones (Q4 NDA submission, FDA pathway 505(b)(2), and planned interim safety analysis), but it does not include a new FDA decision or fresh pivotal readout beyond what is already framed as ongoing.
Market effects
Reinforces investor focus on sustained-release intravitreal delivery platforms and trial design elements (patient selection, loading/screening) in wet AMD.
Limited direct regional spillover; primarily impacts US-listed ophthalmology/biotech sentiment.
Could influence global wet AMD competitive read-through if the 505(b)(2) pathway and durability claims gain traction with regulators internationally.
Counterpoint
The transcript emphasizes durability and post-hoc AI dryness metrics, which may not fully translate into regulatory or payer outcomes without primary endpoint strength in SOL-R.
Key entities
- companyOcular Therapeutix
Subject of the earnings call transcript discussing AXPAXLI wet AMD development and NDA planning.
- productAXPAXLI
Intravitreal sustained-release maintenance agent using axitinib delivered via a bioresorbable hydrogel.
- regulatorFDA
Regulatory counterpart for NDA submission timing and pathway selection (505(b)(2)).
- clinical_trialsSOL-1 and SOL-R
Phase III wet AMD trials with different objectives and patient selection/loading designs.



